Group 1 - The stock price of Weisi Medical (688580) closed at 65.7 yuan on January 9, 2026, representing a 35.74% increase from the previous week's closing price of 48.4 yuan [1] - The stock reached a nearly one-year high of 72.27 yuan on January 7, 2026, and recorded a low of 51.9 yuan on January 5, 2026 [1] - The company has a current market capitalization of 6.292 billion yuan, ranking 62nd out of 127 in the medical device sector and 2932nd out of 5182 in the A-share market [1] Group 2 - Weisi Medical's stock experienced abnormal trading fluctuations, with a cumulative price deviation of over 30% for three consecutive days, leading to its appearance on the "Dragon and Tiger List" on January 6, 2026 [2][3] - The company confirmed that there are no undisclosed matters affecting its operations, and its business remains stable [2] - For the first three quarters of 2025, Weisi Medical reported revenue of 326 million yuan, an increase of 11.58% year-on-year, and a net profit attributable to shareholders of 102 million yuan, reflecting a year-on-year growth of 30.68% [2][3]

Core Viewpoint - Weisi Medical (688580) has experienced significant stock price movement, with a closing price of 69.7 yuan on January 6, 2026, marking a 20.01% increase and achieving a consecutive two-day limit-up [1]. Group 1: Trading Information - On January 6, 2026, the net inflow of main funds was 8.11 million yuan, indicating increased attention from institutional investors [3][6]. - The stock was listed on the "Dragon and Tiger List" due to its price increase deviation reaching 15% and a cumulative increase of 30% over three trading days [4][6]. Group 2: Company Announcements - Weisi Medical announced that its stock price had deviated significantly, with a cumulative increase exceeding 30% over three consecutive trading days, but confirmed that there were no undisclosed major issues and that operations remain normal [5]. - The company focuses on rehabilitation medical devices, with its brain-computer interface products still in the early stages of market cultivation and contributing limited revenue [5][6]. - For the first three quarters of 2025, Weisi Medical reported a revenue of 326 million yuan, representing a year-on-year growth of 11.58%, and a net profit attributable to shareholders of 102 million yuan, reflecting a year-on-year increase of 30.68% [5][6].

Core Viewpoint - The company announced that its stock experienced an abnormal fluctuation, with a cumulative closing price increase exceeding 30% over three consecutive trading days in late December 2025 and early January 2026, but there are no undisclosed significant matters affecting its operations [1] Financial Performance - As of the end of 2025, the company's new brain-computer interface products are in the early stages of market cultivation and have not yet achieved large-scale sales, contributing limited revenue [1] - For the first three quarters of 2025, the company reported revenue of 326 million yuan, representing a year-on-year increase of 11.58% [1] - The net profit for the same period was 102 million yuan, reflecting a year-on-year growth of 30.68% [1] Investor Advisory - The company has reminded investors to be cautious and to consider risks when investing [1]